Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

692
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
692
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

161
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
161
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Cardiovascular Medicine And Haematology
  9. Cardiovascular Medicine And Haematology Not Elsewhere Classified
  11. Avatrombopag For The Salvage Treatment Of Platelet Transfusion Refractoriness.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Cardiovascular Medicine And Haematology
  9. Cardiovascular Medicine And Haematology Not Elsewhere Classified
  11. Avatrombopag For The Salvage Treatment Of Platelet Transfusion Refractoriness.

Related Experiment Video

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.7K

Avatrombopag for the salvage treatment of platelet transfusion refractoriness.

Yuehong Qin1, Yu Wang1, Yujiao Zhang1

  • 1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Therapeutic Advances in Hematology
|March 14, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Avatrombopag effectively treats refractory platelet transfusion refractoriness (PTR) in hematologic patients, improving platelet response and survival rates compared to best available therapies. This thrombopoietin receptor agonist offers a safe and viable treatment option for PTR.

Keywords:
avatrombopagplatelet responseplatelet transfusion refractorinessthrombocytopenia

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

853
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

15.9K

Related Experiment Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.7K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

853
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

15.9K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Platelet transfusion refractoriness (PTR) presents a significant clinical challenge in hematological patients.
  • Thrombopoietin receptor agonists, like avatrombopag, show potential in managing platelet production and immune tolerance.

Purpose of the Study:

  • To compare avatrombopag (Ava) with best available therapies (BATs) in refractory PTR patients.
  • Evaluate platelet response (PR), bleeding events, and mortality rates between treatment groups.

Main Methods:

  • Retrospective data collection from 71 refractory PTR patients.
  • Comparison of PR, transfusion independence, bleeding events, and survival between Ava (n=41) and BATs (n=30) groups.

Main Results:

thrombopoietin receptor agonists
  • 75.6% of Ava patients achieved PR versus 13.3% in BATs group within 3 months.
  • Ava group showed higher platelet counts, improved transfusion independence, and better overall survival (OS) and bleeding event-free survival (EFS).
  • Avatrombopag was identified as a protective factor for OS and EFS, with no intolerability issues.

Conclusions:

  • Avatrombopag demonstrates efficacy and safety as a treatment for refractory PTR.
  • This study supports avatrombopag as a valuable therapeutic option for patients with refractory PTR.